BackBlueprint Medicines Overview

Blueprint Medicines Receivables

Blueprint Medicines's receivables is $80M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$79.80M
↑ 32.90% YoYΔ $19.75M vs prior year quarter

Peer average

Loading

Blueprint Medicines Receivables History

Loading

Blueprint Medicines vs. peers: Receivables Comparison

Loading

Blueprint Medicines Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Blueprint Medicines (BPMC) FAQ

As of the most recent data (March 2025), BPMC shows a receivables of $80M. That compares with $60M in the prior-year period — up 32.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BPMC's receivables is now $80M (was $60M) — a 32.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Blueprint Medicines is outperforming or lagging.

Tracking BPMC's receivables over time shows whether Blueprint Medicines is scaling, shrinking, or reshaping that part of the business. The current reading is $80M That compares with $60M in the prior-year period — up 32.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Blueprint Medicines's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $80M) with ownership activity and broader fundamentals.

Blueprint Medicines's receivables is $80M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.